Biomarkers for risk stratification of patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: Insights from the Platelet Inhibition and Patient Outcomes trial.

[1]  C. Held,et al.  Biomarkers in Relation to the Effects of Ticagrelor in Comparison With Clopidogrel in Non–ST-Elevation Acute Coronary Syndrome Patients Managed With or Without In-Hospital Revascularization: A Substudy From the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2014, Circulation.

[2]  M. Pencina,et al.  Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. , 2014, Annals of Internal Medicine.

[3]  V. Hasselblad,et al.  Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. , 2013, International journal of cardiology.

[4]  C. Berry,et al.  Randomized trial of preventive angioplasty in myocardial infarction. , 2013, The New England journal of medicine.

[5]  Jane A. Linderbaum,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[6]  Deepak L. Bhatt,et al.  2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Circulation.

[7]  J. Ravkilde,et al.  Sex- and age-related differences in clinical outcome after primary percutaneous coronary intervention. , 2012, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[8]  B. Gersh.  Association Between Adoption of Evidence-Based Treatment and Survival for Patients With ST-Elevation Myocardial Infarction , 2012 .

[9]  W. Gao,et al.  Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside , 2011, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[10]  Akiko Maehara,et al.  A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.

[11]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[12]  P. Damman,et al.  MULTIPLE BIOMARKERS AT ADMISSION SIGNIFICANTLY IMPROVE THE PREDICTION OF MORTALITY IN PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION , 2013 .

[13]  Marc P. Bonaca,et al.  Growth Differentiation Factor-15 and Risk of Recurrent Events in Patients Stabilized After Acute Coronary Syndrome: Observations From PROVE IT-TIMI 22 , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[14]  P. Armstrong,et al.  A Model for Predicting Mortality in Acute ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention: Results From the Assessment of Pexelizumab in Acute Myocardial Infarction Trial , 2010, Circulation. Cardiovascular interventions.

[15]  A. Dyer,et al.  beta-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. , 2010, American heart journal.

[16]  A. Jaffe,et al.  Analytical validation of a high-sensitivity cardiac troponin T assay. , 2010, Clinical chemistry.

[17]  L. Lind,et al.  Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study. , 2009, European heart journal.

[18]  W. Ahmad.  Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes. , 2009 .

[19]  M. Jeong,et al.  N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention. , 2009, International journal of cardiology.

[20]  A. Skene,et al.  Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. , 2009, American heart journal.

[21]  J. Alpert,et al.  Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction , 2008 .

[22]  L. Wallentin,et al.  Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction. , 2007, European heart journal.

[23]  Jeroen J. Bax,et al.  Universal definition of myocardial infarction. , 2007 .

[24]  G. Brabant,et al.  Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay. , 2007, Clinical chemistry.

[25]  K. Eagle,et al.  Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE) , 2006, BMJ : British Medical Journal.

[26]  P. Armstrong,et al.  Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction. , 2006, European heart journal.

[27]  B. Gersh,et al.  Prediction of mortality after primary percutaneous coronary intervention for acute myocardial infarction: the CADILLAC risk score. , 2005, Journal of the American College of Cardiology.

[28]  M. Sabatine,et al.  Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. , 2004, Journal of the American College of Cardiology.

[29]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[30]  M. Pencina,et al.  Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation , 2004, Statistics in medicine.

[31]  Felix Zijlstra,et al.  Prognostic Assessment of Patients With Acute Myocardial Infarction Treated With Primary Angioplasty: Implications for Early Discharge , 2004, Circulation.

[32]  A. Larsson,et al.  Biochemical indicators of cardiac and renal function in a healthy elderly population. , 2004, Clinical biochemistry.

[33]  H. Katus,et al.  Admission Troponin T Level Predicts Clinical Outcomes, TIMI Flow, and Myocardial Tissue Perfusion After Primary Percutaneous Intervention for Acute ST-Segment Elevation Myocardial Infarction , 2001, Circulation.

[34]  E. Antman,et al.  TIMI Risk Score for ST-Elevation Myocardial Infarction: A Convenient, Bedside, Clinical Score for Risk Assessment at Presentation: An Intravenous nPA for Treatment of Infarcting Myocardium Early II Trial Substudy , 2000, Circulation.